$IDXG Cashflow Statement | Understand Stock

$IDXG

$6.91 +$0.40 (6.18%) Close

$IDXG Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From Operating Activities
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Bad debt recovery
Mark to market on warrants
Goodwill impairment
Intangible asset impairment
Interest accretion expense
Asset impairment - lab supplies
Amortization of deferred financing fees
Accrued interest - note payable
Interest - note payable
Note payable fees
Stock-based compensation
Amortization on operating lease right of use asset
ESPP expense
Deferred taxes
Change in fair value of note payable
Deferred income taxes
Loss on DiamiR transaction
Change in fair value of contingent consideration
Other gains and expenses, net
Other changes in operating assets and liabilities:
Accounts receivable
Other current assets
Other long-term assets
Accounts payable
Accrued salaries and bonus
Accrued liabilities
Operating lease liabilities
Long-term liabilities

Net cash provided by operating activities
Cash Flows From Investing Activity
Proceeds from sale of Interpace Pharma Solutions, net
Purchase of property and equipment
Sale of property and equipment
Net cash used in investing activities

Cash Flows From Financing Activities
Issuance of common stock, net of expenses
Loan proceeds - related parties
Loan proceeds - BroadOak
Loan expenses - BroadOak
Payments made on note payable
Financing fees - related party
Series C conversion costs
Payment of BroadOak terminal payment
Proceeds from convertible debt issuance
Borrowings on line of credit
Payments on line of credit
Cash paid for repurchase of restricted shares
Net cash used in financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents from continuing operations – beginning
Cash and cash equivalents from discontinued operations – beginning
Cash and cash equivalents – beginning
Cash and cash equivalents from continuing operations – ending
Cash and cash equivalents from discontinued operations – ending
Cash and cash equivalents – ending

Comments